pre-IPO PHARMA

context-therapeutics PRESS RELEASE ARCHIVE

Jan 11, 2023

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics and Leadartis - ResearchAndMarkets.com


Aug 2, 2022

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination USA - English USA - English Deutschland - Deutsch Latin America - español España - español


Jul 1, 2020

Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results


Jul 1, 2020

Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results


Mar 12, 2020

Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER



Mar 12, 2020

Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER


Jan 7, 2020

Context Therapeutics to Present at Biotech Showcase 2020


Jan 7, 2020

Context Therapeutics to Present at Biotech Showcase 2020


Oct 7, 2019

Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast Cancer


Oct 7, 2019

Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast Cancer



Sep 19, 2019

Context Therapeutics and Jefferson Health to Evaluate Apristor Combination Therapy for Women with Advanced Endometrial Cancer


Sep 19, 2019

Context Therapeutics and Jefferson Health to Evaluate Apristor Combination Therapy for Women with Advanced Endometrial Cancer


Sep 16, 2019

Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor


Sep 16, 2019

Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor


May 2, 2019

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor in Progesterone Receptor Positive Gynecological Cancers



May 2, 2019

Context Therapeutics and World-Renowned Cancer Center Announce a Phase 2 Trial for Apristor in Progesterone Receptor Positive Gynecological Cancers


Dec 18, 2018

Context Therapeutics Announces Key Additions to its Board of Directors


Dec 18, 2018

Context Therapeutics Announces Key Additions to its Board of Directors


Oct 23, 2018

Context Therapeutics Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor in Progesterone Receptor Positive Cancers


Oct 23, 2018

Context Therapeutics Reports Encouraging Phase 1 Safety and Efficacy Data of Apristor in Progesterone Receptor Positive Cancers



Aug 8, 2018

Context Therapeutics Signs Strategic Research Collaborations for Apristor (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields


Aug 8, 2018

Context Therapeutics Signs Strategic Research Collaborations for Apristor (onapristone extended release) With Key Academic Leaders in the Progesterone Receptor (PR) and Breast Cancer Fields


Apr 27, 2018

Context Therapeutics Co-Founder and CEO Martin Lehr Named Ernst and Young 2018 Entrepreneur of the Year Semifinalist


Apr 27, 2018

Context Therapeutics Co-Founder and CEO Martin Lehr Named Ernst and Young 2018 Entrepreneur of the Year Semifinalist


Jan 16, 2018

Context Therapeutics Announces the Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast Cancer



Jan 16, 2018

Context Therapeutics Announces the Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast Cancer


Nov 16, 2017

Context Therapeutics Announces Senior Leadership Appointments


Nov 16, 2017

Context Therapeutics Announces Senior Leadership Appointments


Nov 15, 2017

ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement


Aug 17, 2017

Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1



Aug 17, 2017

Context Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of Sigma1


Jul 19, 2017

Context Therapeutics Announces Appointment of Erard Gilles as Chief Medical Officer


Jul 19, 2017

Context Therapeutics Announces Appointment of Erard Gilles as Chief Medical Officer


Google Analytics Alternative